Myeloma, Multiple Clinical Trial
Official title:
A Phase I, Open-Label, Multi-Center Study of CKD-581 in Combination With Lenalidomide and Dexamethasone in Patients With Previously Treated Multiple Myeloma
This study is to determine the maximum tolerated dose(MTD) and recommened phase 2 dose(RP2D) based on dose limiting toxicity(DLT), and to evaluate safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Lenalidomide and Dexamethasone in patients with Previously Treated Multiple Myeloma.
This is an open label, dose escalation study. Cohort of 3~6 patients receive escalation doses of CKD-516 until the maximum tolerated dose(MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04009109 -
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
|
Phase 2 | |
| Terminated |
NCT03910439 -
Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT03966443 -
Fluciclovine PET/CT in Multiple Myeloma Patients
|
||
| Recruiting |
NCT03051841 -
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02294487 -
Study of the Immune Response After Vaccination in Multiple Myeloma Patients
|
||
| Recruiting |
NCT04645199 -
National Longitudinal Cohort of Hematological Diseases
|
||
| Completed |
NCT02033928 -
Comprehensive Frailty Assessment
|
N/A |